Cancer clinical trials in the region Île-de-France

787 currently recruiting clinical trials
Region Île-de-France
Phase 1 / Phase 2 Lymphoma CLL & Richter's syndrome #NCT05006716
Required histologic types
B cell lymphoma CLL (Chronic Lymphocytic Leukemia) Richter's syndrome
Required histologic sub types
Large B cell lymphoma Mantel cell lymphoma Follicular lymphoma Marginal zone lymphoma Waldenström lymphoma Lymphocytic lymphoma
Required central nervous system lesions
None
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
9 recruiting sites
BeOne Medecines
Phase 1 / Phase 2 Breast cancer #NCT04585750 #2023-504251-27-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
Other KRAS KRAS G12C KRAS G12D KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT04585750 #2023-504251-27-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
Other KRAS KRAS G12C KRAS G12D KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Endometrial cancer #NCT04585750 #2023-504251-27-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
Other KRAS KRAS G12C KRAS G12D KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Lung cancer #NCT04585750 #2023-504251-27-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded genetic anomalies
KRAS G12C KRAS G12D KRAS non G12C
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Ovarian / Fallopian tubes / Peritoneum cancer #NCT04585750 #2023-504251-27-00
Required histologic types
Epithelial ovarian cancer
Required histologic sub types
Serous high grade carcinoma (HGSOC)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
TP53
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
PMV Pharmaceuticals, Inc
Phase 1 / Phase 2 Prostate cancer #NCT07190300 #2025-521873-15-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Hormone therapy
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Internal Vectorised Radiotherapy (IVR)
3 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Stomach and esophageal cancer #NCT06445972 #2023-509306-29-00
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 1 / Phase 2 Stomach and esophageal cancer #NCT06469944 #2023-509307-33-00
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
HER2
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Antibody Drug Conjugates (ADC)
2 recruiting sites
Merck Sharp & Dohme LLC
Phase 1 / Phase 2 Pancreas cancer Stomach and esophageal cancer #NCT06005493 #2023-000154-20
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
2 recruiting sites
AstraZeneca